Update date
31 Dec 2025
Sources and sharing
GNTA - Genenta Science S.p.A. Research and Development Expense
- Context
- Latest reported period: 2025
- Latest reported value
- €2,699,342
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Tracking and update notes
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Dec 2025
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: 2025.
- Latest reported value on this page: €2,699,342.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Research and Development Expense
Latest reported research and development expense: €2,699,342. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
2025
SEC-backed company facts were refreshed from filings filed on 01 Apr 2026.
Benchmark Context
How Research and Development Expense compares with peers
Genenta Science S.p.A. sits in the upper half of the current research and development expense sample.
Compared with
Compared with 6 companies reporting research and development expense in EUR. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 1x the current sample midpoint. Research and Development Expense is down about 44% versus the comparable prior period.
- Visible rows currently span reported period ends from 31 Dec 2024 to 31 Dec 2025.
- Nearby companies in this sample: EDAP TMS SA and Coda Octopus Group, Inc..
- Current sample position: rank #3 of 6 comparable companies.
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Plain-English Guide
What Research and Development Expense means
R&D expense is what the company reports spending on research and development during the period.
Why people care
It helps users understand how heavily the company is investing in future products, platforms, or technology.
How to read it
Compare R&D with revenue and operating income so you can see whether innovation spending is growing faster than the rest of the business.
Compare next
Compare it with revenue, operating income, and capex to understand the mix between current spending and long-term investment.
R&D intensity varies widely by industry, so peer comparisons are most useful when businesses are genuinely comparable.
Open a live SEC-backed example
Financial Metric Page
Genenta Science S.p.A.: Research and Development Expense
Latest period: 2025. Period end: 31 Dec 2025. Units: EUR. Frequency: annual and quarterly.
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Metric snapshot
- Latest value
- €2,699,342
- Coverage range
- 31 Dec 2021 - 31 Dec 2025
- Fact rows
- 6
What this metric tells you
- Shows reported research and development expense over 31 Dec 2021 - 31 Dec 2025.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 6 SEC fact rows for this metric and issuer.
How to read this chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use annual sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC source
Source: SEC company facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
- View financial facts overview
- Genenta Science S.p.A. SEC filings
- Latest 10-Q/10-K hub
- Open SEC company facts
Direct filing link is shown only when a matched SEC filing document is available for this metric context.
Compare This Metric Across Companies
Compare latest available Research and Development Expense levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
Genenta Science S.p.A. appears at rank #3 in the latest comparison sample.
Which companies spend the most on R&D?
| Rank | Company | Latest value | Report period | Next step |
|---|---|---|---|---|
| 1 | ASML HOLDING NV (asml) | €4,698,800,000 | Year - 31 Dec 2025 | Open ASML HOLDING NV Research and Development Expense |
| 2 | EDAP TMS SA (focl) | €7,726,000 | Year - 31 Dec 2024 | Open EDAP TMS SA Research and Development Expense |
| 3 | Genenta Science S.p.A. (gnta) | €2,699,342 | Year - 31 Dec 2025 | Open Genenta Science S.p.A. Research and Development Expense |
| 4 | Coda Octopus Group, Inc. (coda) | €2,447,762 | Year - 31 Oct 2025 | Open Coda Octopus Group, Inc. Research and Development Expense |
| 5 | Sono Group N.V. (ssm) | €417,000 | Quarter - 31 Dec 2025 | Open Sono Group N.V. Research and Development Expense |
| 6 | DYADIC INTERNATIONAL INC (dyai) | €187,939 | Instant - 30 Sep 2025 | Open DYADIC INTERNATIONAL INC Research and Development Expense |
Metric Details
- Metric
- Research and Development Expense (ResearchAndDevelopmentExpense)
- Frequency coverage
-
annual and quarterly
Comparability: Compare annual with annual and quarterly with quarterly
- Taxonomy
- us-gaap
- Units tracked
- EUR
- History range
-
31 Dec 2021 - 31 Dec 2025
Freshness: From parsed SEC XBRL facts on this page
- Facts on this page
-
6
Source: SEC company facts API
- Metric definition
-
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service a new process or technique in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use during the reporting period charged to research development projects including the costs of developing computer software up to the point in time of achieving technological feasibility costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
- SEC metric endpoint
- Open SEC company concept
Metric identity
Names, identifiers, and filing context for this profile.
1 identity field
Metric coverage
3 source fields
How to read it
1 detail
Source evidence
Original filing metadata and source links for verification.
1 source field
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Research and Development Expense, Annual (EUR)
Research and Development Expense, YoY Annual Change (%)
Research and Development Expense, Quarterly (EUR)
Genenta Science S.p.A. Annual Research and Development Expense (EUR)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | €2,699,342 | -€2,113,512 | -44% | 01 Jan 2025 | 31 Dec 2025 | 20-F | 01 Apr 2026 | 2025 | FY |
| 2024 | €4,812,854 | -€1,661,587 | -26% | 01 Jan 2024 | 31 Dec 2024 | 20-F | 01 Apr 2026 | 2025 | FY |
| 2023 | €6,474,441 | +€1,135,479 | +21% | 01 Jan 2023 | 31 Dec 2023 | 20-F | 01 Apr 2026 | 2025 | FY |
| 2022 | €5,338,962 | +€1,948,285 | +57% | 01 Jan 2022 | 31 Dec 2022 | 20-F | 28 Mar 2025 | 2024 | FY |
| 2021 | €3,390,677 | -€1,297,784 | -28% | 01 Jan 2021 | 31 Dec 2021 | 20-F | 29 Mar 2024 | 2023 | FY |
Genenta Science S.p.A. Quarterly Research and Development Expense (EUR)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q1 2022 | €158,000 | 27 Apr 2022 | 20-F | 21 Apr 2023 | 2022 | FY |
* marks a reported value that did not pass the local value check.